September 24, 2026 PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward Enrollment
September 24, 2026 Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
September 24, 2026 Coave Therapeutics to Present New Data on Wet AMD Gene Therapy Program at 26th Euretina Congress as it Advances towards the Clinic
